pioglitazone has been researched along with Congestive Ophthalmopathy in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Excerpt | Relevance | Reference |
---|---|---|
"Until now, the following are not known: (1) the mechanisms underlying the induction of chemokine (C-X-C motif) ligand 10 (CXCL10) secretion by cytokines in thyrocytes; (2) if pioglitazone is able, like rosiglitazone, to inhibit the interferon (IFN)-γ-induced chemokine expression in Graves disease (GD) or ophthalmopathy (GO); and (3) the mechanisms underlying the inhibition by thiazolidinediones of the cytokines-induced CXCL10 release in thyrocytes." | 7.77 | Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. ( Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Paolicchi, A; Piaggi, S; Salvi, M, 2011) |
"Until now, the following are not known: (1) the mechanisms underlying the induction of chemokine (C-X-C motif) ligand 10 (CXCL10) secretion by cytokines in thyrocytes; (2) if pioglitazone is able, like rosiglitazone, to inhibit the interferon (IFN)-γ-induced chemokine expression in Graves disease (GD) or ophthalmopathy (GO); and (3) the mechanisms underlying the inhibition by thiazolidinediones of the cytokines-induced CXCL10 release in thyrocytes." | 3.77 | Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. ( Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Paolicchi, A; Piaggi, S; Salvi, M, 2011) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cheng, AM | 1 |
Yin, HY | 1 |
Chen, A | 1 |
Liu, YW | 1 |
Chuang, MC | 1 |
He, H | 1 |
Tighe, S | 1 |
Sheha, H | 1 |
Liao, SL | 1 |
Antonelli, A | 3 |
Ferrari, SM | 3 |
Fallahi, P | 3 |
Frascerra, S | 2 |
Santini, E | 1 |
Franceschini, SS | 2 |
Ferrannini, E | 3 |
Piaggi, S | 1 |
Paolicchi, A | 1 |
Salvi, M | 1 |
Ruffilli, I | 1 |
Pupilli, C | 1 |
Bernini, G | 1 |
Sellari-Franceschini, S | 1 |
Gelmini, S | 1 |
4 other studies available for pioglitazone and Congestive Ophthalmopathy
Article | Year |
---|---|
Celecoxib and Pioglitazone as Potential Therapeutics for Regulating TGF-β-Induced Hyaluronan in Dysthyroid Myopathy.
Topics: Adult; Blotting, Western; Case-Control Studies; Celecoxib; Cells, Cultured; Cyclooxygenase 2 Inhibit | 2016 |
Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Topics: Adipocytes; Cells, Cultured; Chemokine CXCL11; Chemokine CXCL9; Dose-Response Relationship, Drug; En | 2009 |
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
Topics: Adipocytes; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Chemokine CXCL10; Femal | 2011 |
β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.
Topics: Cells, Cultured; Chemokine CCL2; Chemokine CXCL10; Fenofibrate; Fibroblasts; Graves Ophthalmopathy; | 2012 |